Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy

Lancet. 1984 Apr 21;1(8382):894-6. doi: 10.1016/s0140-6736(84)91350-3.

Abstract

46 adults with previously untreated acute myelogenous leukaemia who achieved complete remission with 6-thioguanine, cytarabine, and daunorubicin (TAD) received two courses of intensive consolidation chemotherapy. The first cycle consisted of 5-azacytidine and doxorubicin followed by a second consolidation cycle with TAD. Maintenance chemotherapy was not administered. Median remission duration was 14 months and 26% (95% confidence interval, 11%-41%) remained in continuous remission at 5 years. Actuarial 5 year survival was 31% (+/- 15%). Results were most favourable in patients who achieved complete remission within 60 days of chemotherapy being initiated. These data indicate that prolonged disease-free survival can be achieved in patients treated with intensive induction and consolidation treatment alone without maintenance chemotherapy.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Azacitidine / administration & dosage
  • Cytarabine / administration & dosage
  • Daunorubicin / administration & dosage
  • Drug Administration Schedule
  • Female
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / mortality*
  • Male
  • Middle Aged
  • Recurrence
  • Thioguanine / administration & dosage
  • Time Factors

Substances

  • Cytarabine
  • Thioguanine
  • Azacitidine
  • Daunorubicin

Supplementary concepts

  • DAT protocol 1